Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.

Digestive diseases and sciences - 1 Mar 2003

Thuluvath Paul J, Pande Hemant, Maygers Joyce

Abstract excerpt

Standard therapies for the treatment of hepatitis C are ineffective in almost 50% of patients. Amantadine is an antiviral agent that may have activity against hepatitis C virus. In this pilot study, we evaluated the efficacy of a combination of interferon, ribavirin, and amantadine in patients with chronic hepatitis C who had previously failed 6-12 months of treatment with interferon and ribavirin. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amantadine
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Liver Function Tests

Share to Pilot Projects

Share to Ribavirin

Share to Treatment Failure

Source

Identifiers

PMID: 12757175
DOI: 10.1023/a:1022509304694

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.PMID 12757175Read ↗

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.Semantic proximity Read ↗

A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.Semantic proximity Read ↗

Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.Semantic proximity Read ↗

Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).Semantic proximity Read ↗

No beneficial effects of amantadine in treatment of chronic hepatitis C patients.Semantic proximity Read ↗

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.Semantic proximity Read ↗

[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].Semantic proximity Read ↗

A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.Semantic proximity Read ↗

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.Semantic proximity Read ↗

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.Semantic proximity Read ↗

Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.